Tech Center 1600 • Art Units: 1621 1629
This examiner grants 61% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17789374 | ARGINASE INHIBITORS AND METHODS OF USE | Non-Final OA | MERCK SHARP & DOHME LLC |
| 19300296 | Additive for Food, Drink and Pharmaceutical Products to Improve Health and Well-Being | Non-Final OA | RB2 Enterprises, LLC |
| 19285330 | PHARMACEUTICAL COMPOSITION COMPRISING MELOXICAM | Non-Final OA | Mylan Laboratories LTD |
| 17616930 | ALTERNATIVE PROCESS FOR THE PREPARATION OF 4-PHENYL-5-ALKOXYCARBONYL-2-THIAZOL-2-YL-1,4-DIHYDROPYRIMIDIN-6-YL]METHYL]-3-OXO-5,6,8,8A-TETRAHYDRO-1H-IMIDAZO[1,5-A]PYRAZIN-2-YL]-CARBOXYLIC ACID | Final Rejection | Hoffmann-La Roche Inc. |
| 18035671 | PROTEIN-PROTEIN INTERACTION MODULATORS OF AURORA KINASE A AND THEIR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | Non-Final OA | EBERHARD KARLS UNIVERSITÄT TÜBINGEN |
| 18780069 | METHODS OF TREATMENT OF PRIMARY BILIARY CHOLANGITIS | Non-Final OA | Ipsen Pharma |
| 18301361 | METHODS FOR THE TREATMENT OF PRESBYOPIA | Non-Final OA | LENZ Therapeutics Operations, Inc. |
| 17797368 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | Final Rejection | Neurocrine Biosciences, Inc. |
| 18443904 | MEK-INHIBITOR FOR THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS | Non-Final OA | ATRIVA THERAPEUTICS GMBH |
| 17995904 | Hydroxyureamethyl-Acylfulvene for Treating Brain Cancer or CNS Cancer | Final Rejection | Lantern Pharma Inc. |
| 18249134 | COMBINATIONS OF BCL-2 INHIBITORS WITH CHEMOTHERAPEUTIC AGENTS | Non-Final OA | RECURIUM IP HOLDINGS, LLC |
| 18033167 | INTRANASAL ADMINISTRATION OF SURAMIN FOR TREATING NERVOUS SYSTEM DISORDERS | Non-Final OA | PaxMedica, Inc. |
| 18249228 | Compositions and Uses Thereof | Non-Final OA | Purposeful IKE |
| 18043269 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | Non-Final OA | CULLGEN (SHANGHAI), INC. |
| 18043000 | PHARMACEUTICALLY ACCEPTABLE SALT OF CARIPRAZINE AND CRYSTAL FORM THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Final Rejection | SHANGHAI BOCIMED PHARMACEUTICAL CO., LTD. |
| 18015002 | SATRAPLATIN FOR USE IN THE TREATMENT OF LYMPHOID NEOPLASMS | Final Rejection | pharma& Schweiz GmbH |
| 18013155 | COMPOUNDS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | Final Rejection | University of Delhi |
| 18009899 | BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | Non-Final OA | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH CHINESE ACADEMY OF SCIENCES |
| 17875368 | PARAXANTHINE-BASED CAFFEINE SUBSTITUTE COMPOSITIONS AND METHOD OF USE THEREOF IN SLOW CAFFEINE METABOLIZERS | Non-Final OA | Ingenious Ingredients, LP |
| 17620956 | METHYLTHIONINIUM AS ENHANCERS OF THE COGNITIVE FUNCTION | Final Rejection | WisTa Laboratories Ltd. |
| 17920588 | AFMT ANALOGS AND THEIR USE IN METHODS OF TREATING PARKINSON'S DISEASE | Final Rejection | President and Fellowes of Harvard College |
| 17642153 | COMPOSITIONS FOR THE TREATMENT OF SOLID TUMORS | Non-Final OA | Raziel Therapeutics Ltd. |
| 17762519 | PHARMACEUTICAL COMPOUNDS AND METHODS OF USE | Final Rejection | DERMCARE-VET PTY LTD |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy